- Home
- DHF vs SCPH Comparison
DHF vs SCPH Comparison
Compare DHF & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHF
- SCPH
- Stock Information
- Founded
- DHF 1998
- SCPH 2013
- Country
- DHF United States
- SCPH United States
- Employees
- DHF N/A
- SCPH N/A
- Industry
- DHF Finance Companies
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- DHF Finance
- SCPH Health Care
- Exchange
- DHF Nasdaq
- SCPH Nasdaq
- Market Cap
- DHF 189.1M
- SCPH 299.0M
- IPO Year
- DHF N/A
- SCPH 2017
- Fundamental
- Price
- DHF $2.62
- SCPH $5.63
- Analyst Decision
- DHF
- SCPH Buy
- Analyst Count
- DHF 0
- SCPH 3
- Target Price
- DHF N/A
- SCPH $12.00
- AVG Volume (30 Days)
- DHF 451.1K
- SCPH 2.4M
- Earning Date
- DHF 01-01-0001
- SCPH 11-12-2025
- Dividend Yield
- DHF 7.65%
- SCPH N/A
- EPS Growth
- DHF N/A
- SCPH N/A
- EPS
- DHF N/A
- SCPH N/A
- Revenue
- DHF N/A
- SCPH $49,969,000.00
- Revenue This Year
- DHF N/A
- SCPH $104.30
- Revenue Next Year
- DHF N/A
- SCPH $76.06
- P/E Ratio
- DHF N/A
- SCPH N/A
- Revenue Growth
- DHF N/A
- SCPH 107.79
- 52 Week Low
- DHF $2.06
- SCPH $1.94
- 52 Week High
- DHF $2.39
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- DHF 56.42
- SCPH 63.64
- Support Level
- DHF $2.57
- SCPH $4.33
- Resistance Level
- DHF $2.63
- SCPH $5.62
- Average True Range (ATR)
- DHF 0.02
- SCPH 0.04
- MACD
- DHF 0.00
- SCPH -0.01
- Stochastic Oscillator
- DHF 75.00
- SCPH 83.33
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.